Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2020
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
BUY
Exercise of conversion of derivative security
|
Direct |
21,460
+31.6%
|
$729,640
$34.96 P/Share
|
|
May 26
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
270
-5.61%
|
$17,550
$65.0 P/Share
|
|
May 26
2020
|
Jonathan E. Mayhew EVP - Transformation |
SELL
Open market or private sale
|
Direct |
10,556
-69.05%
|
$686,140
$65.0 P/Share
|
|
May 14
2020
|
Fernando Aguirre Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,865
+7.86%
|
$115,630
$62.31 P/Share
|
|
May 14
2020
|
C David Brown Ii Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,986
+1.67%
|
$123,132
$62.31 P/Share
|
|
May 14
2020
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,955
+9.44%
|
$121,210
$62.31 P/Share
|
|
May 14
2020
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,694
+3.32%
|
$291,028
$62.31 P/Share
|
|
May 14
2020
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,865
+50.0%
|
$115,630
$62.31 P/Share
|
|
May 14
2020
|
Mary L Schapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,487
+36.25%
|
$154,194
$62.31 P/Share
|
|
May 14
2020
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,955
+5.56%
|
$121,210
$62.31 P/Share
|
|
May 11
2020
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Open market or private purchase
|
Direct |
5,000
+24.8%
|
$315,000
$63.13 P/Share
|
|
Apr 28
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
6,234
-56.41%
|
$405,210
$65.0 P/Share
|
|
Apr 03
2020
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,803
-1.84%
|
$539,165
$55.72 P/Share
|
|
Apr 03
2020
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-1.42%
|
$55,935
$55.72 P/Share
|
|
Apr 03
2020
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,598
-3.32%
|
$87,890
$55.72 P/Share
|
|
Apr 03
2020
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,944
-5.53%
|
$216,920
$55.72 P/Share
|
|
Apr 03
2020
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,179
-2.03%
|
$119,845
$55.72 P/Share
|
|
Apr 01
2020
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
8,868
-1.71%
|
$514,344
$58.34 P/Share
|
|
Apr 01
2020
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,774
-1.26%
|
$102,892
$58.34 P/Share
|
|
Apr 01
2020
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,806
-2.77%
|
$104,748
$58.34 P/Share
|
|
Apr 01
2020
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,552
-1.49%
|
$90,016
$58.34 P/Share
|
|
Apr 01
2020
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,109
-2.42%
|
$64,322
$58.34 P/Share
|
|
Apr 01
2020
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
1,481
-12.72%
|
$85,898
$58.34 P/Share
|
|
Apr 01
2020
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
973
-3.75%
|
$56,434
$58.34 P/Share
|
|
Apr 01
2020
|
Jonathan E. Mayhew EVP - Transformation |
SELL
Payment of exercise price or tax liability
|
Direct |
763
-4.75%
|
$44,254
$58.34 P/Share
|
|
Apr 01
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,713
+27.63%
|
$447,354
$58.34 P/Share
|
|
Apr 01
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-5.67%
|
$39,498
$58.34 P/Share
|
|
Mar 30
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
3,030
-23.69%
|
$181,800
$60.0 P/Share
|
|
Mar 30
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,030
+19.15%
|
$163,620
$54.53 P/Share
|
|
Feb 28
2020
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,202
-12.52%
|
$365,918
$59.18 P/Share
|
|
Feb 28
2020
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,587
+27.29%
|
$1,096,633
$59.18 P/Share
|
|
Feb 28
2020
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
13,330
-8.22%
|
$786,470
$59.18 P/Share
|
|
Feb 28
2020
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
33,795
+29.28%
|
$1,993,905
$59.18 P/Share
|
|
Feb 28
2020
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,255
-8.44%
|
$546,045
$59.18 P/Share
|
|
Feb 28
2020
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,346
+18.77%
|
$1,495,414
$59.18 P/Share
|
|
Feb 28
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,912
+11.49%
|
$112,808
$59.18 P/Share
|
|
Feb 28
2020
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
347
-3.43%
|
$20,473
$59.18 P/Share
|
|
Feb 28
2020
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
BUY
Grant, award, or other acquisition
|
Direct |
1
+0.01%
|
$59
$59.18 P/Share
|
|
Feb 28
2020
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
1,524
-3.2%
|
$89,916
$59.18 P/Share
|
|
Feb 28
2020
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
BUY
Grant, award, or other acquisition
|
Direct |
3,379
+11.97%
|
$199,361
$59.18 P/Share
|
|
Feb 28
2020
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
11,828
+29.74%
|
$697,852
$59.18 P/Share
|
|
Feb 28
2020
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
160
-1.89%
|
$9,440
$59.18 P/Share
|
|
Feb 28
2020
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
51,714
-9.38%
|
$3,051,126
$59.18 P/Share
|
|
Feb 28
2020
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
114,058
+17.15%
|
$6,729,422
$59.18 P/Share
|
|
Feb 28
2020
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
13,457
-17.95%
|
$793,963
$59.18 P/Share
|
|
Feb 28
2020
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
31,683
+29.71%
|
$1,869,297
$59.18 P/Share
|
|
Feb 28
2020
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,366
+17.66%
|
$3,738,594
$59.18 P/Share
|
|
Feb 28
2020
|
Derica W Rice EVP & President, CVS Caremark |
SELL
Payment of exercise price or tax liability
|
Direct |
8,079
-23.15%
|
$476,661
$59.18 P/Share
|
|
Feb 28
2020
|
Derica W Rice EVP & President, CVS Caremark |
BUY
Grant, award, or other acquisition
|
Direct |
21,943
+38.6%
|
$1,294,637
$59.18 P/Share
|
|
Feb 27
2020
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
844
-3.98%
|
$49,796
$59.33 P/Share
|